Drugs / Mitizodone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04984512 | Dec 2021 → Jul 2027 expected | major depressive disorder | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitizodone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04984512 ↗ |
| Route | Oral | “Mitizodone Phosphate tablet 10mg ,orally,once daily for 8 weeks, then placebo,orally,once daily for 2 weeks.” NCT04984512 ↗ |